People: Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

19 Jul 2019
Change (% chg)

$-0.29 (-2.87%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Azelby, Robert 

Mr. Robert W. Azelby is appointed as President, Chief Executive Officer, Director of the Company effective June 13, 2018. Mr. Azelby has served as our President and Chief Executive Officer since June 2018. From November 2015 to May 2018, Mr. Azelby served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics, Inc. From June 2012 to October 2015, Mr. Azelby served as Vice President and General Manager, Oncology at Amgen Inc. From October 2010 to May 2012, he served as Amgen’s Vice President, Amgen Oncology Sales. Prior to that, he served in various positions at Amgen, including periods as Vice President, Commercial Effectiveness Unit and General Manager of Amgen Netherlands. Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. from April 2017 to March 2018. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School. The Nominating and Corporate Governance Committee believes that Mr. Azelby is qualified to serve on our Board of Directors due to his experience in the biopharmaceutical industry, including his operational experience and strong track record in both large and small biopharmaceutical environments.

Basic Compensation

Total Annual Compensation, USD 330,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD 209,034
All Other, USD 9,591,760
Fiscal Year Total, USD 10,130,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Azelby


Carlos Campoy


Erin Lavelle


James Bucher


Randal Hassler


Nadia Dac

As Of  31 Dec 2018